Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 10,232,010

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,232,010
Title:Compositions and methods for treatment of radiation exposure
Abstract: The present invention relates to an immunostimulant and to the use of an immunostimulant in the form of a cross-linked muramyl dipeptide microparticle in the treatment of radiation exposure, radiation poisoning, and mitigating the toxic effects of radiotherapy.
Inventor(s): Gelder; Frank B. (Half Moon Bay, NZ), Webster; Gillian Alison (Waiatarua, NZ)
Assignee: Innate Immunotherapeutics Limited (Auckland, NZ)
Application Number:13/121,796
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,232,010
Patent Claims:see list of patent claims

Details for Patent 10,232,010

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 1991-02-20 ⤷  Free Forever Trial 2028-09-30
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 2000-06-28 ⤷  Free Forever Trial 2028-09-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.